Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709471 | 0.92 | RAB9A (0.53) | ALDH1A1MAPK1MAPTSMN1; SMN2LMNA | |
| SCHEMBL6709571 | 0.84 | SMN1; SMN2 (0.46) | ALDH1A1MAPTSMN1; SMN2LMNANPC1 | |
| SCHEMBL6711076 | 0.84 | SMN1; SMN2 (0.46) | ALDH1A1MAPTSMN1; SMN2LMNANPC1 | |
| SCHEMBL6711242 | 0.82 | TP53 (0.57) | ALDH1A1MAPTSMN1; SMN2LMNANPC1 | |
| SCHEMBL6711089 | 0.80 | RAB9A (0.45) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6712562 | 0.76 | MAPK1 (0.47) | ALDH1A1MAPK1GAAMAPTSMN1; SMN2 | |
| SCHEMBL7851411 | 0.76 | ALDH1A1 (0.45) | ALDH1A1MAPK1MAPTSMN1; SMN2LMNA | |
| SCHEMBL28750323 | 0.72 | NPC1 (0.52) | ALDH1A1SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL17478630 | 0.71 | NPC1 (0.55) | ALDH1A1SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL5519869 | 0.70 | KDM4E (0.41) | ALDH1A1GAAMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-02-05 | — | — | US | disclosed |
| US-6653307-B2 | Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-1292575-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001098275-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, IRF3 | ALDH1A1 668/4885MAPK1 1160/4885GAA 720/4885 |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, ZC3HAV1L | ALDH1A1 463/4885MAPK1 1162/4885GAA 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.